| Identification | Back Directory | [Name]
3,6,9-Acridinetriamine, N9-[3-(dimethylamino)propyl]-N3,N3,N6,N6-tetramethyl- | [CAS]
2187367-10-6 | [Synonyms]
3,6,9-Acridinetriamine, N9-[3-(dimethylamino)propyl]-N3,N3,N6,N6-tetramethyl- | [Molecular Formula]
C22H31N5 | [MOL File]
2187367-10-6.mol | [Molecular Weight]
365.52 |
| Chemical Properties | Back Directory | [Boiling point ]
569.8±50.0 °C(Predicted) | [density ]
1.143±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: 25mg/mL, clear | [form ]
powder | [pka]
12.89±0.30(Predicted) | [color ]
yellow to orange |
| Hazard Information | Back Directory | [Biological Activity]
3,6-DMAD is also called as N9-(3-(dimethylamino)propyl)-N3,N3,N6,N6-tetramethylacridine-3,6,9-triamine. It prevents the development of multiple myeloma (MM) tumor xenografts.''3,6-DMAD is an acridine derivative th at selectively suppresses ER stress- (300 nM Thapsigargin) induced HT1080 cellular XBP1 mRNA splicing (Eff. conc. 500 nM)but not eIF2a phosphorylationby directly inhibiting IRE1? RNase (endoribonuclease) activity and disrupting IRE1α oligomerization. 3,6-DMAD is shown to exhibit anti-multiple myeloma efficacy in cultures in vitro (%survival/[3,6-DMAD]/cell line/24 h = 13%/4 M/RPMI 8226 and 8%/1 μM/MM1.R) and completely suppress the expansion of established RPMI 8226 tumor in mice in vivo when administered via intraperitoneal injection (10 mg/kg q.o.d.). |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|